DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Challenges of Accessing and Analyzing Real World Data

Thinking about getting started in real world data? Here are the challenges you should be aware of before you begin.

There continues to be a great deal of buzz around real world data. For biopharmaceutical companies raised on conventional market research, the ability to now access data pulled directly from insurance claims and electronic health records (EHR) translates to a major upgrade in analytical muscle. At least, that’s the theory.

In practice, real world data projects are extremely challenging. The data is expensive to buy, time-consuming to process, and requires a great deal of analytical and therapeutic expertise to turn into reliable, meaningful, actionable insights. But done right, real world data has the potential to boost brand performance, fine-tune commercial strategy, tease out subtle market nuances, and unlock hidden opportunities.

In a recent interview, DRG’s Mladen Tomich discusses the challenges of accessing and analyzing real world data for pharma companies.

 

Contact us to learn how DRG's therapeutic experts can help you transform real world data into actionable insights.